Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT (CMV_TCR-001)
CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy With CMV TCR-transduced Donor-derived T Cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation
Sponsor: University College, London
Suspended
Protocol being re-written to allow inclusion of more patients
This PHASE1 trial investigates CMV Infection and Haematological Malignancies and is currently suspended. University College, London leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Suspended PHASE1
-
Oct 2018 — Jan 2021 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Jan 2017 — May 2017 [monthly]
Suspended PHASE1
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .